Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians

D Moris, M Palta, C Kim, PJ Allen… - CA: a cancer journal …, 2023 - Wiley Online Library
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and
remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients …

[HTML][HTML] Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review

A Rizzo, G Brandi - Cancer treatment and research communications, 2021 - Elsevier
Biliary tract cancers (BTCs) comprise a heterogenous group of aggressive and rare
malignancies arising in the bile duct outside or within the liver. BTCs include …

Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

A Vogel, J Bridgewater, J Edeline… - Annals of …, 2023 - annalsofoncology.org
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ -
Annals of Oncology Skip to Main Content Advertisement Annals of Oncology European Society …

Systematic review and meta-analysis of prognostic factors for early recurrence in intrahepatic cholangiocarcinoma after curative-intent resection

WJ Choi, PJ Williams, MPAW Claasen, T Ivanics… - Annals of surgical …, 2022 - Springer
Background Recurrence rates of intrahepatic cholangiocarcinoma (iCCA) after curative
hepatectomy are as high as 50% to 70%, and about half of these recurrences occur within 2 …

Adjuvant and neoadjuvant therapies for hepatocellular carcinoma

A Vogel, RC Grant, T Meyer, G Sapisochin… - Hepatology, 2023 - journals.lww.com
Immune-oncology based regimens have shown efficacy in advanced hepatocellular
carcinoma and have been implemented as standard of care as first line therapy. Their …

[HTML][HTML] Development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma

GW Ji, CY Jiao, ZG Xu, XC Li, K Wang, XH Wang - BMC cancer, 2022 - Springer
Background Accurate prognosis assessment is essential for surgically resected intrahepatic
cholangiocarcinoma (ICC) while published prognostic tools are limited by modest …

[HTML][HTML] Recurrent intrahepatic cholangiocarcinoma–review

Y Bekki, D Von Ahrens, H Takahashi… - Frontiers in …, 2021 - frontiersin.org
Intrahepatic cholangiocarcinoma (ICC) is the second-most common primary liver
malignancy after hepatocellular carcinoma. While surgical resection with negative margin is …

[HTML][HTML] Surgical treatment of intrahepatic cholangiocarcinoma: current and emerging principles

EW Beal, JM Cloyd, TM Pawlik - Journal of Clinical Medicine, 2020 - mdpi.com
Intrahepatic cholangiocarcinoma (ICC) is a rare, aggressive cancer of the biliary tract. It often
presents with locally advanced or metastatic disease, but for patients with early-stage …

Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? Implications from the neoadjuvant experience

MC Mason, NN Massarweh, CWD Tzeng… - Annals of surgical …, 2021 - Springer
Background While surgery is a mainstay of curative-intent treatment for patients with
intrahepatic cholangiocarcinoma (IHC), the role of neoadjuvant therapy (NT) has not been …

Higher tumor burden status dictates the impact of surgical margin status on overall survival in patients undergoing resection of intrahepatic cholangiocarcinoma

Y Endo, K Sasaki, Z Moazzam, HA Lima… - Annals of Surgical …, 2023 - Springer
Background The present study aimed to examine the prognostic significance of margin
status following hepatectomy of intrahepatic cholangiocarcinoma (ICC) relative to overall …